A

ABL Bio Inc
KOSDAQ:298380

Watchlist Manager
ABL Bio Inc
KOSDAQ:298380
Watchlist
Price: 186 800 KRW -1.99% Market Closed
Market Cap: 10.3T KRW

ABL Bio Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ABL Bio Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
A
ABL Bio Inc
KOSDAQ:298380
Cash from Operating Activities
-â‚©23.6B
CAGR 3-Years
18%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash from Operating Activities
â‚©872.8B
CAGR 3-Years
36%
CAGR 5-Years
16%
CAGR 10-Years
19%
SK Bioscience Co Ltd
KRX:302440
Cash from Operating Activities
-â‚©128B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Cash from Operating Activities
-â‚©29.1B
CAGR 3-Years
-18%
CAGR 5-Years
3%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash from Operating Activities
â‚©149.5B
CAGR 3-Years
32%
CAGR 5-Years
45%
CAGR 10-Years
25%
Alteogen Inc
KOSDAQ:196170
Cash from Operating Activities
â‚©86.5B
CAGR 3-Years
N/A
CAGR 5-Years
74%
CAGR 10-Years
43%
No Stocks Found

ABL Bio Inc
Glance View

ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.

ABL Bio Inc Intrinsic Value
HIDDEN
Show

See Also

What is ABL Bio Inc's Cash from Operating Activities?
Cash from Operating Activities
-23.6B KRW

Based on the financial report for Jun 30, 2025, ABL Bio Inc's Cash from Operating Activities amounts to -23.6B KRW.

What is ABL Bio Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-13%

Over the last year, the Cash from Operating Activities growth was 70%. The average annual Cash from Operating Activities growth rates for ABL Bio Inc have been 18% over the past three years , -13% over the past five years .

Back to Top